KRAS and gastric cancer: Although trastuzumab is expected to be an effective molecular target drug for ERBB2 alterations, which were observed in gastric cancers, there are no effective drugs currently available for KRAS and APC alterations, which are frequently observed in other organs, or for TP53 alterations, which are frequently observed in digestive cancers.